M&A · Healthcare · Surgical & Medical Instruments & Apparatus
Virtual Therapeutics Corporation to acquire Akili, Inc.
Announced May 29, 2024 · Closed Jul 2, 2024
Deal value—
Premium85.0%To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash
Transaction
- Acquirer
- Virtual Therapeutics Corporation
- Target
- Akili, Inc.
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Jul 2, 2024
Deal protections
- Break fee (target pays)
- $1.1M
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- TD Cowen
- TD Cowen fee
- $3.0M
Sector context · Healthcare
- Comparable deals
- 107 in the prior 24 months
- Premium
- 85.0% vs. 63.0% sector median
- EV / Adj. EBITDA
- Sector median 17.2x
- Break fee
- Sector median 3.5%
Timeline
- AnnouncedMay 29, 2024
- Tender offerJun 3, 2024
- ClosedJul 2, 2024
Valuation · fairness opinions
Discounted cash flow$0.25$0.37
Implied value per Akili, Inc. share by analysis, from TD Cowen.